Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)

Pragmatic trial: 47 patients with prior MRD <10^-5, ≥1 year of maintenance, and prospectively confirmed undetectable disease by PET, BM flow (10^-5), and BM clonoSEQ (10^-6) discontinued maintenance (median prior maintenance 36 months). Median post-discontinuation follow-up 30 months. Baseline MRD ≥10^-7 in 9/47 (19%). Estimated 3-year cumulative incidence of disease resurgence was 20% if baseline MRD <10^-7 vs 75% if ≥10^-7 (HR 7.8, 95% CI 2.2-27.6, P=0.001); 3-year PFS 92% vs 49% (HR 10.1, 95% CI 1.6-62.3). Small single-arm study (level 3).

Blood Cancer JPubMed 39375362